LP16198-1

Methotrexate

Active

Descriptions

High-dose methotrexate (MTX) is an antimetabolite drug used in treatment of cancer, and low-dose methotrexate (MTX) is used as a disease modifying antirheumatic drug (DMARD) for long-term treatment of rheumatoid arthritis (RA), psoriasis, and other autoimmune diseases. Methotrexate is a first-line drug in RA treatment. One challenge in the use of the drug is that about 30% of patients do not respond to treatment or experience adverse effects, such as gastrointestinal symptoms, malaise, and psychological complaints. PMID: 20665136 Source: Regenstrief LOINC, PMID: 20665136

An anti-neoplastic anti-metabolite with immunosuppressant properties. It inhibits tetrahydrofolate dehydrogenase and prevents the formation of tetrahydrofolate, an essential component of DNA, necessary for synthesis of thymidylate. Source: National Library of Medicine, MeSH 2006

Basic Part Properties

Part Display Name

Methotrexate

Part Type

Component (Describes the core component or analyte measured)

Created On

2000-05-04

Construct for LOINC Short Name

MTX

Related Codes

LOINC Terminology Service (API) using HL7^® FHIR^® Get Info

Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.

CodeSystem lookup

https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=LP16198-1

ConceptMap translate

https://fhir.loinc.org/ConceptMap/$translate?system=http://loinc.org&code=LP16198-1

Language Variants Get Info

LOINC Copyright

Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright © 1995-2024, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. See https://loinc.org/license for the full LOINC copyright and license.